---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-009078"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2022-04-05T23:59:59+00:00"
generated_at: "2026-06-26T09:35:34.194070+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Provectus eliminates Series B Preferred Stock, increases Series D-1 authorized shares

## Summary
- Filed Certificate of Elimination for Series B Convertible Preferred Stock; all shares converted to common on Aug 25, 2021.
- Filed Certificate of Amendment increasing authorized Series D-1 Preferred Stock from 9,441,000 to 11,241,000 shares.
- Both actions effective March 30, 2022.

## SEC filing metadata
- accession: 0001493152-22-009078
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2022-04-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315222009078/0001493152-22-009078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315222009078/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-009078
- JSON: https://secwatch.observer/filing/0001493152-22-009078.json
- Plain text: https://secwatch.observer/filing/0001493152-22-009078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.